SciNeuro In-Licenses China Rights to Lilly Treatment for Parkinson's

Shanghai 's SciNeuro Pharma in-licensed Greater China rights to Lilly's alpha-synuclein targeted antibody therapies, an expected therapy for Parkinson's. SciNeuro will make an upfront payment along with downstream milestones and royalties, though details were not disclosed. In December 2020, SciNeuro was launched with $100 million from Lilly Asia Ventures and Arch Venture Partners to develop CNS therapies for China . Min Li, PhD, a Venture Partner at Lilly Asia Ventures, is Founder and CEO of SciNeuro. The Lilly deal is SciNeuro's first in-licensing. More details.... Stock Symbol: (NYSE: LLY) Share this with colleagues: // //